Published: June 08, 2010
New Hope for Early Breast Cancer Detection
HOUSTON - (BUSINESS WIRE) - In the U.S., one out of eight women will develop breast cancer in her
lifetime. The earlier the breast cancer is found, the more likely a
woman will live a normal life, said Stephen Rose, M.D., a breast
radiologist at Memorial Hermann Memorial City.
Since April, the Bobetta Lindig Breast Care Center at Memorial Hermann
Memorial City Medical Center has been participating in a clinical trial
of a new imaging technology called breast tomosynthesis. The trial will
compare breast tomosynthesis in combination with conventional digital
mammography. There is no additional cost for the tomosynthesis research
study.
"Many women have dense breast tissue. On a conventional mammogram, it
can look similar to cancer," said Dr. Rose, principal investigator for
the Houston study. "Breast tomosynthesis allows us to see multiple
slices of the breast, which improves our ability to see a malignancy
that may be hidden by overlapping tissue."
Breast tomosynthesis is a three-dimensional (3-D) imaging technology
that involves a small number of low dose images of a breast in a short
(5 second) scan. A powerful computer is then used to reconstruct the
images into a series of thin high-resolution slices. Reconstructed
tomosynthesis slices reduce or eliminate the problems caused by tissue
overlap and structure noise in conventional two-dimensional (2-D)
mammography. Breast tomosynthesis also offers a number of exciting
opportunities, including improved diagnostic and screening accuracy,
fewer recalls, greater radiologist confidence, and 3D lesion
localization.
Dr. Rose predicts he'll see fewer false positive results with breast
tomosynthesis. And because the images are clearer, he believes
radiologists will have the capability to see smaller lesions than what
can be seen on a conventional mammogram.
"We're very excited about breast tomosynthesis because we can look at
isolated areas of the breast in greater detail," added Dr. Rose.
Breast tomosynthesis is available commercially in Europe and Canada but
not yet approved for use in the United States. Hospitals including
Memorial Hermann Memorial City are gathering data for FDA approval. The
clinical trial is sponsored in part by Hologic, manufacturer of the
breast tomosynthesis system used in the trial.
For more information, call 877-9-MAMMO-0.

Breast Center
Robin Judman, 713-242-3717 or 713-242-3716
robin.judman@memorialhermann.org
or
Rose
Imaging Scheduling
Tina Chen, 877-9-MAMMO-0
houstonbreastimaging.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News